Radezolid Explained

Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Melinta Therapeutics, Inc. for the treatment of bacterial acne.^[1]

Further reading

• Zhou J, Bhattacharjee A, Chen S, etal . Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics . Bioorg. Med. Chem. Lett. . 18 . 23 . 6175–8 . December 2008 . 18947996 . 10.1016/j.bmcl.2008.10.011.
• Skripkin E, McConnell TS, DeVito J, etal . Rχ-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance . Antimicrob. Agents Chemother. . 52 . 10 . 3550–7 . October 2008 . 18663023 . 2565890 . 10.1128/AAC.01193-07.
• Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J . In vitro activities of the Rχ-01 oxazolidinones against hospital and community pathogens . Antimicrob. Agents Chemother. . 52 . 5 . 1653–62 . May 2008 . 18316525 . 2346622 . 10.1128/AAC.01383-07.
• Hanselmann R, Job G, Johnson G, Lou R, Martynow JG, Reeve MM . Synthesis of an antibacterial compound containing a 1,4-substituted 1H-1,2,3-triazole- a scaleable [sic?] alternative to the "click" reaction" . 2009 . Organic Process Research & Development . 10.1021/op900252a . 14 . 152–158.
• Franceschi F, Duffy EM . Structure-based drug design meets the ribosome . Biochem. Pharmacol. . 71 . 7 . 1016–25 . March 2006 . 16443192 . 10.1016/j.bcp.2005.12.026.
• Ohlsen K . Novel antibiotics for the treatment of Staphylococcus aureus . Expert Rev. Clin. Pharmacol. . 2 . 6 . 661–72 . November 2009 . 10.1586/ecp.09.26. 22112259 . 36016568 .

Notes and References

1. News: Stearns. John. Melinta Therapeutics takes aim at deadly drug-resistant bacteria. Hartford Business Journal. August 1, 2016.